Curcumin implants, not curcumin diet, inhibit estrogen-induced mammary carcinogenesis in ACI rats

Cancer Prevention Research

Volumn 7, Issue 4, 2014, Pages 456-465

  Bansal, Shyam S ^a,b   Kausar, Hina ^b   Vadhanam, Manicka V ^b   Ravoori, Srivani ^b   Pan, Jianmin ^b   Rai, Shesh N ^b   Gupta, Ramesh C ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; CYTOCHROME P450 1A; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; ESTRADIOL; PROLACTIN; ANTINEOPLASTIC AGENT; CYP1B1 PROTEIN, RAT; CYP3A2 PROTEIN, RAT; CYTOCHROME P450 1A1; CYTOCHROME P450 3A; ESTROGEN;

ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CONTROLLED STUDY; DIET; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG IMPLANT; DRUG TISSUE LEVEL; ENZYME ACTIVITY; ENZYME METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RAT; SILICONE PROSTHESIS; TUMOR VOLUME; ANIMAL; AUGUST COPENHAGEN IRISH RAT; BIODEGRADABLE IMPLANT; CELL TRANSFORMATION; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION; TOXICITY;

ABSORBABLE IMPLANTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CURCUMIN; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1B1; CYTOCHROME P-450 CYP3A; DIET; ESTROGENS; FEMALE; LIVER; MAMMARY NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED ACI; TISSUE DISTRIBUTION;

EID: 84898880876     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0248     Document Type: Article

References (44)

1. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 2009;30:85-94.
2. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008;267:133-64.
3. Bansal SS, Goel M, Aqil F, Vadhanam MV, Gupta RC. Advanced drug-delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res 2011;4:1158-71.
4. Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis 2007;28:1765-73. (Pubitemid 47289040)
5. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm 2007;4:807-18.
6. Shaikh J, Ankola DD, Beniwal V, Singh D, Kumar MN. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharm Sci 2009;37:223-30.
7. Wang D, Veena MS, Stevenson K, Tang C, Ho B, Suh JD, et al. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor κB by an AKT-independent pathway. Clin Cancer Res 2008;14:6228-36.
8. Shahani K, Swaminathan SK, Freeman D, Blum A, Ma L, Panyam J. Injectable sustained release microparticles of curcumin: a new concept for cancer chemoprevention. Cancer Res 2010;70:4443-52.
9. Ma Z, Haddadi A, Molavi O, Lavasanifar A, Lai R, Samuel J. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin. J Biomed Mater Res A 2008;86:300-10. (Pubitemid 351969628)
10. Boriwanwattanarak P, Ingkaninan K, Khorana N, Viyoch J. Development of curcuminoids hydrogel patch using chitosan from various sources as controlled-release matrix. Int J Cosmet Sci 2008;30:205-18. (Pubitemid 351623838)
11. Lee MH, Lin HY, Chen HC, Thomas JL. Ultrasound mediates the release of curcumin from microemulsions. Langmuir 2008;24:1707-13. (Pubitemid 351500922)
12. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 2007;60:171-7. (Pubitemid 46742531)
13. Bansal SS, Kausar H, Aqil F, Jeyabalan J, Vadhanam MV, Gupta RC, et al. Curcumin implants for continuous systemic delivery: safety and biocompatibility. Drug Deliv Trans Res. 2011;1:332-41.
14. Gupta RC, Bansal SS, Aqil F, Jeyabalan J, Cao P, Kausar H, et al. Controlled-release systemic delivery - a new concept in cancer chemoprevention. Carcinogenesis 2012;33:1608-15.
15. Bansal SS, Kausar H, VadhanamMV, Ravoori S, Gupta RC. Controlled systemic delivery by polymeric implants enhances tissue and plasma curcumin levels compared with oral administration. Eur J Pharm Biopharm 2012;80:571-7.
16. Ravoori S, Vadhanam MV, Sahoo S, Srinivasan C, Gupta RC. Mammary tumor induction in ACI rats exposed to low levels of 17β-estradiol. Int J Oncol 2007;31:113-20.
17. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985;150:76-85. (Pubitemid 16258399)
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
19. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data. 2nd ed. New York: Springer Verlag; 2003.
20. Shull JD, Spady TJ, Snyder MC, Johansson SL, Pennington KL. Ovaryintact, but not ovariectomized female ACI rats treated with 17β-estradiol rapidly develop mammary carcinoma. Carcinogenesis 1997;18:1595-601. (Pubitemid 28134784)
21. Jeyabalan J, Aqil F, Munagala R, Annamalai L, Vadhanam MV, Gupta RC. Chemopreventive and therapeutic activity of dietary blueberry against estrogen-mediated breast cancer. J Agric Food Chem 2013 Nov 18. [Epub ahead of print].
22. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27. (Pubitemid 36223277)
23. Welsch CW, Jenkins TW, Meites J. Increased incidence of mammary tumors in the female rat grafted with multiple pituitaries. Cancer Res 1970;30:1024-9.
24. Malejka-Giganti D, Niehans GA, Reichert MA, Bliss RL. Post-initiation treatment of rats with indole-3-carbinol or β-naphthoflavone does not suppress 7,12-dimethylbenz[a]anthracene-induced mammary gland carcinogenesis. Cancer Lett 2000;160:209-18.
25. Malejka-Giganti D, Parkin DR, Bennett KK, Lu Y, Decker RW, Niehans GA, et al. Suppression of mammary gland carcinogenesis by post-initiation treatment of rats with tamoxifen or indole-3-carbinol or their combination. Eur J Cancer Prev 2007;16:130-41.
26. Grubbs CJ, Steele VE, Casebolt T, Juliana MM, Eto I, Whitaker LM, et al. Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol. Anticancer Res 1995;15:709-16.
27. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10. (Pubitemid 27239511)
28. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27. (Pubitemid 28376821)
29. Huang Z, Guengerich FP, Kaminsky LS. 16α-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis 1998;19:867-72. (Pubitemid 28376780)
30. Malejka-Giganti D, Bennett KK, Culp SJ, Beland FA, Shinozuka H, Bliss RL. Suppression of 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis by pre-initiation treatment of rats with β-naphthoflavone coincides with decreased levels of the carcinogen-derived DNA adducts in the mammary gland. Cancer Detect Prev 2005;29:338-47. (Pubitemid 41267292)
31. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005;227:115-24. (Pubitemid 41174580)
32. Ireson CR, Jones DJ, Orr S, Coughtrie MW, Boocock DJ, Williams ML, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002;11:105-11. (Pubitemid 34118319)
33. Wahlang B, Pawar YB, Bansal AK. Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model. Eur J Pharm Biopharm 2011;77:275-82.
34. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol 2007;595:1-75.
35. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 2013;15:195-218.
36. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 2012;39:283-99.
37. Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol Nutr Food Res 2012;56:454-65.
38. Choudhuri T, Pal S, Agarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett 2002;512:334-40. (Pubitemid 34164505)
39. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005;280:20059-68. (Pubitemid 41379535)
40. Carroll CE, Benakanakere I, Besch-Williford C, Ellersieck MR, Hyder SM. Curcumin delays development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors. Menopause 2010;17:178-84.
41. Huang MT, Lou YR, Xie JG, Ma W, Lu YP, Yen P, et al. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene- induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis 1998;19:1697-700. (Pubitemid 28441876)
42. Pereira MA, Grubbs CJ, Barnes LH, Li H, Olson GR, Eto I, et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane-induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 1996;17:1305-11.
43. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004;10:6847-54. (Pubitemid 39383033)
44. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900. (Pubitemid 33051148)